Skip to content
Agree.net – Lifestyle
Author:
Candel Therapeutics
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 5, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 2, 2026
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
October 29, 2026
Candel Therapeutics to Present at November Investor Conferences
October 27, 2026
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
October 22, 2026
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
October 2, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
October 1, 2026
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
September 30, 2026
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 30, 2026
1
2
3
Next Page
→